

### IL-29, human recombinant protein

Interleukin-29, IL-29, IFN-Lambda 1, Interferon-Lambda 1, Cytokine ZCYTO21, IL29, IFNL1, ZCYTO21.

Catalog # PBV10517r

## **Specification**

# IL-29, human recombinant protein - Product info

Primary Accession Q8IU54
Calculated MW 20 kDa KDa

## IL-29, human recombinant protein - Additional Info

Gene ID 282618
Gene Symbol IL29

**Other Names** 

Interleukin-29, IL-29, IFN-Lambda 1, Interferon-Lambda 1, Cytokine ZCYTO21, IL29, IFNL1, ZCYTO21.

Gene Source Human Source E. coli

Assay&Purity SDS-PAGE; ≥90% Assay2&Purity2 HPLC; ≥90%

Recombinant Yes

**Application Notes** 

Reconstitute in sterile dH $_2$ O not less than 100  $\mu$ g/ml. This solution can then be diluted into other aqueous buffers

#### **Format**

Lyophilized protein

### **Storage**

-20°C; Sterile filtered and lyophilized with no additives

### IL-29, human recombinant protein - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- <u>Immunohistochemistry</u>
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

## IL-29, human recombinant protein - Images

### IL-29, human recombinant protein - Background





Tel: 858.875.1900 Fax: 858.875.1999

IL-29 is distantly related to type I interferons and the IL-10 family. Expression of IL-29 is induced by viral infection which interacts with a heterodimeric class II cytokine receptor that consists of interleukin 10 receptor β (IL10RB) and interleukin 28 receptor α. IL-29 exhibits common features with type I IFNs such as antiviral activity, antiproliferative activity and in vivo antitumour activity. IL-29 acts similarly to IFNs, but is less effective generally and has activity in a more limited range of cell lines. IL-29 produced in response to viral infection, activates both monocytes and macrophages producing a restricted panel of cytokines and therefore is an important factor in activating innate immune responses at the site of viral infection. IFN-Lambda 1 antiviral and antiproliferative activity requires Interferon-Lambda 2 receptor tyrosine residues. Recombinant human IL-29 produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 181 amino acids and having a molecular mass of 20 kDa.